HIV Treatment Bulletin - Vol. 7, No. 6, June 2006
Ben Cheng, HIV i-Base

Brecanavir is a new protease inhibitor that is currently in clinical studies and it is being studied in combination with low dose ritonavir. A drug interaction study involving 48 HIV-negative individuals participated in this study to evaluate the effects of atazanavir and ritonavir on brecanavir drug levels.

The results from the study showed that the addition of atazanavir (300mg once a day) to brecanavir/ritonavir (300mg/100mg every 12 hours) led to higher brecanavir, ritonavir and atazanavir drug levels. AUC levels of all drugs increased: brecanavir by an average of 38%, ritonavir by 56% and atazanavir levels by 44%. Results from this study suggest that atazanavir further increases brecanavir levels on top of the increase already seen with low dose ritonavir and a reduction in the dose of atazanavir should be considered.

Ref: Ford S, Murray S, Anderson M et al. Brecanavir/ritonavir and atazanavir/ritonavir increased following repeat co-administration. 7th International Workshop on Clinical Pharmacology of HIV Therapy, 20-22 April 2006, Lisbon. Abstract 76.

2006-06-10
IB060706-16

©2006. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.